1. Show article details.

    10x Genomics to Report Third Quarter Financial Results on November 3, 2021

    PR Newswire – 4:05 PM ET 10/07/2021

    PLEASANTON, Calif. Live audio of the webcast will be available on the "Investors" section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event. About 10x Genomics10x Genomics (TXG) is a life science technology company building products to interrogate, understand and master biology to advance human health.

  2. Show article details.

    10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

    GlobeNewswire – 4:05 PM ET 08/31/2021

    10x Genomics, Inc. (TXG), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, September 13th, at 2:45 p.m. Eastern Time/11:45 a.m. Pacific Time.

  3. Show article details.

    10x Genomics to Present at the UBS Genomics 2.0 and MedTech Innovations Summit

    GlobeNewswire – 8:00 AM ET 08/06/2021

    10x Genomics, Inc. (TXG), today announced the company will be participating in the upcoming UBS Genomics 2.0 and MedTech Innovations Summit. 10x Genomics’ management is scheduled to present on Tuesday, August 10th at 6:00 p.m. Eastern Time/3 p.m. Pacific Time.

  4. Show article details.

    BRIEF-10X Genomics Reports Q2 2021 Financial Results

    Reuters – 5:47 PM ET 08/04/2021

    10X Genomics Inc (TXG): * 10X GENOMICS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS. * SEES FY REVENUE UP 61 TO 67 PERCENT. * SEES FY REVENUE $480 MILLION TO $500 MILLION. * Q2 REVENUE $115.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $112.8 MILLION. * QTRLY LOSS PER SHARE $0.10. * Q2 EARNINGS PER SHARE VIEW $-0.26 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

  5. Show article details.

    10x Genomics Reports Second Quarter 2021 Financial Results

    GlobeNewswire – 4:05 PM ET 08/04/2021

    10x Genomics, Inc. (TXG) today reported financial results for the second quarter ended June 30, 2021. Recent Highlights "We continued our track record of execution during the second quarter, delivering on major strategic objectives while also delivering on our commercial plans and R&D pipeline," said Serge Saxonov, Co-founder and CEO of 10x Genomics.

  6. Show article details.

    BRIEF-Bio-Rad And 10X Genomics Announce Settlement To Resolve Multiple Litigations

    Reuters – 12:32 PM ET 07/27/2021

    Bio Rad Laboratories Inc (BIO/B): * BIO-RAD AND 10X GENOMICS ANNOUNCE SETTLEMENT TO RESOLVE MULTIPLE LITIGATIONS. * BIO RAD (BIO/B) - RECEIVES BROAD FREEDOM-TO-OPERATE IN SINGLE-CELL MARKET AND MAINTAINS EXCLUSIVITY TO ITS MICROWELL SINGLE-CELL INTELLECTUAL PROPERTY. * BIO RAD (BIO/B) - SETTLEMENT INCLUDES GLOBAL PATENT CROSS-LICENSE FOR PATENTS HELD BY CO, 10X GENOMICS.

  7. Show article details.

    Bio-Rad and 10x Genomics Announce Settlement to Resolve Multiple Litigations

    Business Wire – 12:27 PM ET 07/27/2021

    Bio-Rad Laboratories, Inc. (BIO/B), a global leader of life science research and clinical diagnostic products, today announced that Bio-Rad (BIO/B) and 10x Genomics, Inc. (TXG) have reached a final settlement to resolve multiple long-running litigations in Massachusetts, Delaware, California, Germany, and before the International Trade Commission.

  8. Show article details.

    BRIEF-10X Genomics Inc Says Entered Into A Global Settlement And Cross-License Agreement With Bio-Rad Laboratories, Inc

    Reuters – 7:44 AM ET 07/27/2021

    Bio Rad Laboratories Inc (BIO/B): * 10X GENOMICS INC (TXG) - ENTERED INTO A GLOBAL SETTLEMENT AND CROSS-LICENSE AGREEMENT WITH BIO-RAD LABORATORIES, INC. * 10X GENOMICS INC (TXG) - AGREEMENT RESOLVES ALL OUTSTANDING LITIGATION AND OTHER PROCEEDINGS BETWEEN TWO COS ACROSS ALL JURISDICTIONS AROUND THE WORLD.

  9. Show article details.

    BRIEF-10X Genomics Signs Global Patent Cross License Agreement With Bio-Rad

    Reuters – 6:36 AM ET 07/27/2021

    Bio Rad Laboratories Inc (BIO/B): * 10X GENOMICS SIGNS GLOBAL PATENT CROSS LICENSE AGREEMENT WITH BIO-RAD Source text for Eikon: Further company coverage:

  10. Show article details.

    10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad

    GlobeNewswire – 6:30 AM ET 07/27/2021

    Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes  10x Genomics, Inc. (TXG) today announced that it has entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. (BIO/B). The agreement resolves all outstanding litigation and other proceedings between the two companies across all jurisdictions around the world, and dismissing all infringemen...

  11. Show article details.

    10x Genomics Introduces New Chromium X Series for Single Cell Analysis

    GlobeNewswire – 8:00 AM ET 07/14/2021

    Building on its industry leading position in single cell analysis, 10x Genomics (TXG) today announced commercial availability of its new Chromium X Series, a next-generation platform for single cell analysis.

  12. Show article details.

    10x Genomics to Report Second Quarter Financial Results on August 4, 2021

    GlobeNewswire – 4:03 PM ET 07/07/2021

    10x Genomics (TXG) today announced it will report financial results for the second quarter 2021 after market close on Wednesday, August 4th, 2021. Live audio of the webcast will be available on the “Investors” section of the company website at: www.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event.

  13. Show article details.

    10x Genomics Unlocks Whole Transcriptome Analysis in FFPE Tissues With New Visium Assay, Now Shipping

    GlobeNewswire – 8:00 AM ET 06/10/2021

    10x Genomics, Inc. (TXG) today announced it is shipping its new Visium Spatial Gene Expression for FFPE assay. The product addresses customer demand for whole transcriptome spatial profiling of FFPE tissue blocks, especially in the area of translational research.

  14. Show article details.

    10x Genomics to Participate in Upcoming June Investor Conferences

    GlobeNewswire – 8:00 AM ET 05/24/2021

    10x Genomics, Inc. (TXG), today announced the company will be participating virtually in the following investor conferences: Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: https://investors.10xgenomics.com/. About 10x Genomics10x Genomics (TXG) is a life science technology company building products to interrogate, unders...

  15. Show article details.

    10x Genomics Reports First Quarter 2021 Financial Results

    GlobeNewswire – 4:03 PM ET 05/05/2021

    10x Genomics, Inc. (TXG) today reported financial results for the first quarter ended March 31, 2021. Recent Highlights "We had a solid start to the year highlighted by strong growth across the business and the incredible response to the innovation revealed at our inaugural Xperience event," said Serge Saxonov, Co-founder and CEO of 10x Genomics.

  16. Show article details.

    10x Genomics to Present at the BofA Securities 2021 Virtual Healthcare Conference

    GlobeNewswire – 4:05 PM ET 04/29/2021

    10x Genomics, Inc. (TXG), today announced the company will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Wednesday, May 12th at 3:30 p.m. Eastern Time/12:30 p.m. Pacific Time.

Page:

Today's and Upcoming Events

  • Nov
    03

    TXG to announce Q3 earnings (Confirmed)

Past Events (last 90 days)

  • Aug
    04

    TXG announced Q2 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.